Eighty-seven patients with multidrug-resistant tuberculosis (MDR-TB) diagnosed between
1988 and 1990 were treated with isoniazid and at least three other effective second-line …

Multidrug-resistant tuberculosis, a disease caused by Mycobacterium tuberculosis strains
that are resistant at least to rifampin and isoniazid, entails extended treatment, expensive …

Multidrug-resistant tuberculosis (MDR-TB) is threatening control of TB in many parts of the
world. As a result of limited treatment options, patients have a poor prognosis and low …

Multidrug-resistant tuberculosis (MDRTB) should be defined as tuberculosis with resistance
to at least isoniazid and rifampicin because these drugs are the cornerstone of short-course …

Following nearly 3 decades of neglect, there is now renewed interest in the development of
new drugs for the treatment and prevention of tuberculosis [1]. Three reasons are usually …

SETTING: Two specialised multidrug-resistant tuberculosis (MDR-TB) treatment units in
Cameroon. OBJECTIVE: To assess outcome and adverse drug events with a standardised …

Summary The Lancet Respiratory Medicine Commission on drug-resistant tuberculosis was
published in 2017, which comprehensively reviewed and provided recommendations on …

Current World Health Organization guidelines for the formulation of treatment regimens for
multidrug-resistant tuberculosis (MDR-TB) pay too little attention to the microbiological …

Fluoroquinolones have come to play an important role in the treatment of tuberculosis,
particularly multidrug-resistant tuberculosis (MDRTB)(1). This class of antibiotics, which …

The role of so-called “group 5” second-line drugs as a part of antibiotic therapy for multidrug-
resistant tuberculosis (MDR-TB) is widely debated. We performed an individual patient data …